Juventas Therapeutics Cleared to Begin Phase II Clinical Trial
Cleveland, OH--Juventas Therapeutics has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase II clinical trials of its lead compound, JVS-100, for the treatment of critical limb ischemia. The Company is developing a platform to regenerate damaged tissue by using JVS-100 to recruit stem cells to the site of injury, with an initial focus on cardiovascular disease.
"This is a major milestone for the company," commented President & CEO Rahul Aras, Ph.D. "We now have two major clinical programs in progress, one for heart failure and one for critcal limb ischemia."
JVS-100 codes for Stromal-cell Derived Factor 1 (SDF-1), a naturally occurring substance that is produced in the body at the site of tissue injury and that recruits stem cells to the damaged area. The body stops producing SDF1 shortly after the injury, however. Juventas has shown in several pre-clinical studies that SDF1 applied at the site of damaged tissue, even from old injuries, promotes tissue repair. Read more...
Find Out More About ESP
Managing Director Mike Bunker serves on the Juventas Therapeutics board on behalf of Early Stage Partners